Morning Medical with Dr. Chow
A daily update covering the latest medical & health news from around the world using artificial intelligence. Doctor Chi-Ming Chow is a family physician, general internist, and cardiologist. He is also a Professor of Medicine at the University of Toronto.
Quebec Funding, Drug Trends, and New Weight-Loss Pill Foundayo
In this episode, Dr. Chi-Ming Chow begins by discussing Quebec's funding for English-speaking patients and its potential impact on healthcare access. He then highlights alarming trends in drug use in the United States, focusing on medetomidine and fentanyl, their risks, clinical effects, and challenges in managing these substances. Dr. Chow explores fluvoxamine as a potential treatment for long COVID, examining ongoing research and findings. The episode introduces the new weight-loss pill Foundayo, sharing clinical trial results, applications, benefits, side effects, and safety considerations. The episode concludes with closing remarks and a preview of tomorrow's topics.
Key Points
- Quebec is hiring eleven new patient navigators to help English-speaking patients better access the province's predominantly French-speaking health system.
- U.S. health officials are warning about the dangerous presence of medetomidine in the illicit drug market, particularly when combined with fentanyl.
- A study has shown that fluvoxamine, an antidepressant, may significantly reduce fatigue and improve quality of life for adults suffering from long COVID.
Chapters
| 0:00 | |
| 1:58 | |
| 2:40 | |
| 6:22 | |
| 9:54 | |
| 11:16 | |
| 13:01 |
Transcript
Loading transcript...
- / -